Healthy Inc > Blog > Lamivudine 150mg Zidovudine 300mg
Posted on:

What is lamivudine and zidovudine tablets used for?

In the pharmaceutical industry, the fixed-dose combination (FDC) of Lamivudine (150 mg) and Zidovudine (300 mg) is a foundational dual-NRTI (Nucleoside Reverse Transcriptase Inhibitor) backbone for HIV therapy. As a pharmacist and manufacturer, I view this combination as a critical component of Highly Active Antiretroviral Therapy (HAART), designed to simplify dosing and reduce the “pill burden” for patients.

Primary Clinical Uses

  • HIV-1 Infection: Used in combination with at least one other antiretroviral (such as a Protease Inhibitor or an NNRTI) to manage HIV. It is not a cure but effectively slows the progression of the disease.

  • Post-Exposure Prophylaxis (PEP): It is a standard regimen for healthcare workers or individuals who have had a potential occupational or non-occupational exposure to HIV, usually taken for 28 days.

  • Prevention of Mother-to-Child Transmission (PMTCT): Used during pregnancy and labor to reduce the risk of transmitting HIV to the fetus.

Mechanism of Action: Dual Chain Termination

Both drugs are pro-drugs that must be phosphorylated within the cell to their active triphosphate forms.

Competitive Inhibition: They compete with natural deoxynucleosides for a spot in the viral DNA chain being built by the enzyme Reverse Transcriptase.

The “Fake” Building Block: Because these molecules lack a 3′-hydroxyl group, once they are incorporated into the viral DNA string, no further building blocks can be added.

Viral Suppression: This leads to DNA chain termination, preventing the virus from converting its RNA into DNA and stopping it from integrating into the human host cell’s genome.

The Manufacturer’s Perspective: Technical & Export

From a production standpoint in a WHO-GMP facility, this FDC requires specific attention to stability and bioequivalence:

  • Bioequivalence (BE) Challenges: As a firm owner, you know that achieving BE against the innovator (Combivir) is essential for export. We conduct rigorous dissolution testing in multiple pH media to ensure the release profiles of both APIs meet international standards.

  • Zidovudine Stability: Zidovudine is sensitive to light. At our Mumbai facility, we utilize opaque PVC/PVDC or Alu-Alu blister packaging to prevent degradation and ensure a 36-month shelf life.

  • Market Position: While many markets have moved toward Tenofovir-based backbones, the Lamivudine + Zidovudine combination remains vital for patients who cannot tolerate Tenofovir (e.g., those with renal issues).

  • B2B & Dossiers: We provide the full eCTD Dossier and stability data required for registration in Zone IVb markets (Africa, SE Asia), making this a high-volume product for institutional tenders.

Lamivudine & Zidovudine tablets

Posted on:

What is lamivudine and zidovudine tablets used for?

Lamivudine and Zidovudine: The Backbone of Antiretroviral Therapy

In the complex field of virology and pharmaceutical manufacturing, the combination of Lamivudine (3TC) and Zidovudine (AZT) represents a cornerstone in the management of HIV-1 infection. As a manufacturer and pharmacist, I view this fixed-dose combination (FDC) as a vital tool for increasing patient compliance by reducing “pill burden” while delivering a synergistic attack on viral replication.

The Mechanism: Double Chain Termination

Both Lamivudine and Zidovudine belong to the class of Nucleoside Reverse Transcriptase Inhibitors (NRTIs). They act as “decoy” building blocks.

  • The Process: When the HIV virus attempts to replicate its genetic material, it incorporates these analogs into its DNA chain.

  • The Result: Because these molecules lack the necessary attachment point for the next link, the DNA chain is prematurely terminated. This effectively stops the virus from replicating within the host’s CD4 cells.

  • The Clinical Perspective: Why Use the Combination?

  • Synergy: Research has shown that using these two molecules together is significantly more effective than either drug alone, as they target the reverse transcriptase enzyme at different stages and help delay the development of drug resistance.

  • HIV-1 Management: This combination is typically used as part of a multi-drug regimen (HAART) to reduce viral load to undetectable levels and increase CD4 cell counts.

  • Prophylaxis: It is also a critical component in Post-Exposure Prophylaxis (PEP) and in preventing mother-to-child transmission (MTCT) during labor and delivery.

  • The Manufacturer’s Clinical Warning: Hematologic & Hepatic Monitoring

From a safety and production standpoint, the quality of these tablets must be matched by rigorous clinical oversight.

Anemia & Neutropenia: Zidovudine is known to cause bone marrow suppression. Patients must have their complete blood counts (CBC) monitored regularly.

Lactic Acidosis: As with many NRTIs, there is a risk of lactic acidosis and severe hepatomegaly with steatosis, which requires immediate clinical intervention.

Hepatitis B Co-infection: Lamivudine is also active against the Hepatitis B virus (HBV). If a patient has both HIV and HBV and stops taking this medication, they may experience a severe “flare-up” of their Hepatitis B.

FAQ: Global Clinical & Patient Queries

  • What is the primary use of Lamivudine and Zidovudine tablets? They are used in combination with other antiretroviral agents to treat HIV-1 infection and for post-exposure prophylaxis.

    Can this combination cure HIV? No, it does not cure HIV or AIDS, but it helps manage the virus, reduces the risk of transmission, and prevents opportunistic infections.

  • What are the most common side effects? Patients often report headaches, nausea, malaise, and fatigue. Long-term use requires monitoring for fat redistribution (lipodystrophy).

    Is it safe during pregnancy? Yes, this combination is one of the most studied and frequently used regimens for preventing the transmission of HIV from mother to child.

  • How should the tablets be stored? As a manufacturer, we ensure these are stored in moisture-resistant containers at controlled room temperatures ($15^{\circ}\text{C}$ to $30^{\circ}\text{C}$).

Lamivudine & Zidovudine tablets

Add to cart